🚀 VC round data is live in beta, check it out!
Oncology Institute Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oncology Institute and similar public comparables like Cross Country Healthcare, Oceania Healthcare, LNA Sante, Propel Funeral Partners and more.
Oncology Institute Overview
About Oncology Institute
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.
Founded
2007
HQ
Employees
825
Website
Sectors
Financials (LTM)
EV
$378M
Oncology Institute Financials
Oncology Institute reported last 12-month revenue of $542M and negative EBITDA of ($8M).
In the same LTM period, Oncology Institute generated $85M in gross profit, ($8M) in EBITDA losses, and had net loss of ($45M).
Revenue (LTM)
Oncology Institute P&L
In the most recent fiscal year, Oncology Institute reported revenue of $503M and EBITDA of ($12M).
Oncology Institute expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $542M | XXX | $503M | XXX | XXX | XXX |
| Gross Profit | $85M | XXX | $76M | XXX | XXX | XXX |
| Gross Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| EBITDA | ($8M) | XXX | ($12M) | XXX | XXX | XXX |
| EBITDA Margin | (1%) | XXX | (2%) | XXX | XXX | XXX |
| EBIT Margin | (6%) | XXX | (7%) | XXX | XXX | XXX |
| Net Profit | ($45M) | XXX | ($50M) | XXX | XXX | XXX |
| Net Margin | (8%) | XXX | (10%) | XXX | XXX | XXX |
| Net Debt | — | — | $44M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Oncology Institute Stock Performance
Oncology Institute has current market cap of $307M, and enterprise value of $378M.
Market Cap Evolution
Oncology Institute's stock price is $3.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $378M | $307M | 0.3% | XXX | XXX | XXX | $-0.51 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOncology Institute Valuation Multiples
Oncology Institute trades at 0.7x EV/Revenue multiple, and (48.6x) EV/EBITDA.
EV / Revenue (LTM)
Oncology Institute Financial Valuation Multiples
As of April 11, 2026, Oncology Institute has market cap of $307M and EV of $378M.
Equity research analysts estimate Oncology Institute's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oncology Institute has a P/E ratio of (6.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $307M | XXX | $307M | XXX | XXX | XXX |
| EV (current) | $378M | XXX | $378M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | (48.6x) | XXX | (30.4x) | XXX | XXX | XXX |
| EV/EBIT | (12.5x) | XXX | (10.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 4.5x | XXX | 4.9x | XXX | XXX | XXX |
| P/E | (6.8x) | XXX | (6.1x) | XXX | XXX | XXX |
| EV/FCF | (15.8x) | XXX | (15.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oncology Institute Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Oncology Institute Margins & Growth Rates
Oncology Institute's revenue in the last 12 month grew by 28%.
Oncology Institute's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.
Oncology Institute's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oncology Institute's rule of X is 73% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Oncology Institute Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 28% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Margin | (1%) | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Growth | (239%) | XXX | (137%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 73% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 22% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Oncology Institute Public Comps
See public comps and valuation multiples for other Long-Term Care comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cross Country Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Oceania Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| LNA Sante | XXX | XXX | XXX | XXX | XXX | XXX |
| Propel Funeral Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| Eureka Group Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oncology Institute M&A Activity
Oncology Institute acquired XXX companies to date.
Last acquisition by Oncology Institute was on XXXXXXXX, XXXXX. Oncology Institute acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Oncology Institute
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOncology Institute Investment Activity
Oncology Institute invested in XXX companies to date.
Oncology Institute made its latest investment on XXXXXXXX, XXXXX. Oncology Institute invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Oncology Institute
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oncology Institute
| When was Oncology Institute founded? | Oncology Institute was founded in 2007. |
| Where is Oncology Institute headquartered? | Oncology Institute is headquartered in United States. |
| How many employees does Oncology Institute have? | As of today, Oncology Institute has over 825 employees. |
| Who is the CEO of Oncology Institute? | Oncology Institute's CEO is Daniel Virnich. |
| Is Oncology Institute publicly listed? | Yes, Oncology Institute is a public company listed on Nasdaq. |
| What is the stock symbol of Oncology Institute? | Oncology Institute trades under TOI ticker. |
| When did Oncology Institute go public? | Oncology Institute went public in 2021. |
| Who are competitors of Oncology Institute? | Oncology Institute main competitors are Cross Country Healthcare, Oceania Healthcare, LNA Sante, Propel Funeral Partners. |
| What is the current market cap of Oncology Institute? | Oncology Institute's current market cap is $307M. |
| What is the current revenue of Oncology Institute? | Oncology Institute's last 12 months revenue is $542M. |
| What is the current revenue growth of Oncology Institute? | Oncology Institute revenue growth (NTM/LTM) is 28%. |
| What is the current EV/Revenue multiple of Oncology Institute? | Current revenue multiple of Oncology Institute is 0.7x. |
| Is Oncology Institute profitable? | No, Oncology Institute is not profitable. |
| What is the current EBITDA of Oncology Institute? | Oncology Institute has negative EBITDA and is not profitable. |
| What is Oncology Institute's EBITDA margin? | Oncology Institute's last 12 months EBITDA margin is (1%). |
| What is the current EV/EBITDA multiple of Oncology Institute? | Current EBITDA multiple of Oncology Institute is (48.6x). |
| What is the current FCF of Oncology Institute? | Oncology Institute's last 12 months FCF is ($24M). |
| What is Oncology Institute's FCF margin? | Oncology Institute's last 12 months FCF margin is (4%). |
| What is the current EV/FCF multiple of Oncology Institute? | Current FCF multiple of Oncology Institute is (15.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.